CLRB Cellectar Biosciences
Cellectar Biosciences earnings company data as of 4:48 AM ET 10/23
- 0 of 1 EPS beats
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 12 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 13 Aug | EPS | -0.52 | -0.57 | Miss |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by CLRB's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $50K bought by 2 insiders
- $732 sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Jarrod Longcor COOBuy$25K 8,680 shares at $2.88 +74% to stakeTraded May 7 Filed May 11
-
John Neis DirectorSale$732 198 shares at $3.70 95% of stakeTraded Dec 12, 2025 Filed Dec 16, 2025
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 424B3 | Filing Doc | ||
| S-1/A | FORM S-1/A | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| S-1 | FORM S-1 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 1.01,3.02,8.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 10-K/A | Filing Doc | ||
| 10-K | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.